Results 211 to 220 of about 77,108 (288)

Epigenomics‐guided precision oncology: Chromatin variants in prostate tumor evolution

International Journal of Cancer, Volume 158, Issue 2, Page 314-332, 15 January 2026.
Abstract Prostate cancer is a common malignancy that in 5%–30% leads to treatment‐resistant and highly aggressive disease. Metastasis‐potential and treatment‐resistance is thought to rely on increased plasticity of the cancer cells—a mechanism whereby cancer cells alter their identity to adapt to changing environments or therapeutic pressures to create
Kira Furlano, Tina Keshavarzian, Nadine Biernath, Annika Fendler, Maria de Santis, Joachim Weischenfeldt, Mathieu Lupien   +6 more
wiley   +1 more source

Spectrum mining of immune checkpoint inhibitor-related cutaneous toxicities and analysis of associated factors based on FAERS. [PDF]

Front Pharmacol
Ma S.
europepmc   +1 more source

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

International Journal of Cancer, Volume 158, Issue 2, Page 382-408, 15 January 2026.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert   +7 more
wiley   +1 more source

ROSE12, a novel anti-CTLA-4 FcγRs binding-enhanced antibody activated by extracellular adenosine triphosphate, shows tumor-selective regulatory T-cell depletion and antitumor efficacy without systemic immune activation. [PDF]

J Immunother Cancer
Hayashi H, Tatsumi K, Katada H, Matsuda Y, Tsunenari T, Honda M, Nemoto T, Shimizu S, Miura-Okuda M, Ikuta Y, Ito A, Ogami C, Kato C, Kamimura M, Kibayashi T, Kubo C, Komatsu S, Komori Y, Shinozuka J, Susumu H, Tanno H, Tomii Y, Nakagawa K, Nagano H, Nanami M, Nishito Y, Fujisawa N, Matsushita T, Michisaka S, Yamazaki M, Yoshimoto M, Wakatsuki H, Wakabayashi T, Wada NA, Ueda O, Konishi H, Kashima K, Tanaka H, Endo M, Kitazawa T, Sakaguchi S, Kamata-Sakurai M, Igawa T.   +42 more
europepmc   +1 more source

DNA methyltransferase inhibitors in hematological malignancies and solid tumors

International Journal of Cancer, Volume 158, Issue 2, Page 433-461, 15 January 2026.
Abstract Epigenetic modifications such as DNA methylation play a fundamental role in oncogenesis and the progression of neoplasms neoplasias. DNA methyltransferase inhibitors (DNMTi) constitute a family of therapeutic agents that impede the methylation at the 5‐position on cytosine nucleotides, thereby modulating the epigenetic regulation of tumor ...
Valentin Wenger, Guillermo Garcia‐Manero, Robert Zeiser, Michael Lübbert   +3 more
wiley   +1 more source

Clinical Molecular Pathology and Treatment Developments in Advanced Uveal Melanoma: State of the Art. [PDF]

Oncol Res
Dore S, Sacchi M, Pinna A, Palmieri G, Paliogiannis P.   +4 more
europepmc   +1 more source

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.

New England Journal of Medicine, 2016
A. Eggermont, V. Chiarion-Sileni, J. Grob, R. Dummer, J. Wolchok, H. Schmidt, O. Hamid, C. Robert, P. Ascierto, J. Richards, C. Lebbé, V. Ferraresi, M. Smylie, J. Weber, M. Maio, L. Bastholt, L. Mortier, L. Thomas, S. Tahir, A. Hauschild, Jessica C Hassel, F. Hodi, C. Taitt, V. de Pril, Gaetan de Schaetzen, S. Suciu, A. Testori   +26 more
semanticscholar   +1 more source

A new strategy for melanoma treatment: an investigation of the clinical value of the combination of immune checkpoint inhibitors and oncolytic viruses. [PDF]

Cancer Cell Int
Sui B, Jin X, Zheng X.
europepmc   +1 more source

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.

Journal of Clinical Oncology, 2015
D. Schadendorf, F. Hodi, C. Robert, J. Weber, K. Margolin, O. Hamid, D. Patt, Tai-Tsang Chen, D. Berman, J. Wolchok   +9 more
semanticscholar   +1 more source

Ipilimumab with and without nivolumab in patients with classic Hodgkin lymphoma with progression after PD-1 blockade. [PDF]

Blood Neoplasia
Merryman RW, Kline J, Redd RA, Olszewski H, Welsh E, Pfaff K, Lee H, McDonough M, Ahn IE, Brown JR, Crombie JL, Davids MS, Fisher DC, Jacobsen ED, Jacobson CA, Kim AI, Odejide OO, Parry EM, Ryan CE, Shipp MA, Armand P, Rodig S, Abramson JS, LaCasce AS.   +23 more
europepmc   +1 more source